Beijing Tong Ren Tang Chinese Medicine Company Limited

Research Beijing Tong Ren Tang Chinese Medicine Company Limited (TQR) on Bullrun: market cap EUR 593.47M, P/E 14.0, dividend yield 5.9%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerTQR
• ExchangeF
• CountryHong Kong
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic
• CurrencyEUR
• Market capEUR 593.47M
• P/E14.0
• Dividend yield5.9%
• Financial periodFY2024
• RevenueEUR 1.61B
• Revenue growth5.7%
• Net incomeEUR 500.28M
• Free cash flow-EUR 260.42M
• Gross margin66.1%

Valuation Snapshot

latest market cap is EUR 593.47M; P/E is 14.0; dividend yield is 5.9%.

About Beijing Tong Ren Tang Chinese Medicine Company Limited

Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine products to wholesalers and individuals. It operates through Hong Kong, Mainland China, and Overseas segments. The company also offers Chinese medical consultation and treatment services. It markets its products under the Tong Ren Tang brand name.

Frequently asked questions

What is Beijing Tong Ren Tang Chinese Medicine Company Limited's market cap?

Beijing Tong Ren Tang Chinese Medicine Company Limited's market capitalization is EUR 593.47M.

What is Beijing Tong Ren Tang Chinese Medicine Company Limited's P/E ratio?

Beijing Tong Ren Tang Chinese Medicine Company Limited's price-to-earnings (P/E) ratio is 14.0.

Does Beijing Tong Ren Tang Chinese Medicine Company Limited pay a dividend?

Beijing Tong Ren Tang Chinese Medicine Company Limited has a dividend yield of 5.9%.

What does Beijing Tong Ren Tang Chinese Medicine Company Limited do?

Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine products to wholesalers and individuals. It operates through Hong Kong, Mainland China, and Overseas segments.